The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 30, 2019
Filed:
Feb. 26, 2016
Applicant:
Icell Gene Therapeutics Llc, Stony Brook, NY (US);
Inventors:
Yupo Ma, Stony Brook, NY (US);
Kevin Pinz, Stony Brook, NY (US);
Xun Jiang, Stony Brook, NY (US);
Masayuki Wada, Stony Brook, NY (US);
Kevin Chen, Stony Brook, NY (US);
Assignee:
ICELL GENE THERAPEUTICS LLC, Stony Brook, NY (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/705 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01); C07K 14/725 (2006.01); A61K 39/39 (2006.01); A61K 48/00 (2006.01); A61K 35/15 (2015.01); C12N 15/113 (2010.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/7051 (2013.01); A61K 35/15 (2013.01); A61K 39/0011 (2013.01); A61K 39/39 (2013.01); A61K 48/00 (2013.01); A61K 48/005 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/2806 (2013.01); C07K 16/2809 (2013.01); C07K 16/2812 (2013.01); C07K 16/2896 (2013.01); C12N 15/1138 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/622 (2013.01); C07K 2319/00 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C12N 2310/20 (2017.05); C12N 2740/16043 (2013.01);
Abstract
The present disclosure provides chimeric antigen receptor polypeptides having antigen recognition domains for CD2, CD3, CD4, CD5, CD7, CD8, and CD52 antigens, and polynucleotides encoding for the same. The present disclosure also provides for engineered cells expressing the polynucleotide or polypeptides. In some embodiments, the disclosure provides methods for treating diseases associated with CD2, CD3, CD4, CD5, CD7, CD8, and CD52 antigens.